[Effects of lactitol on fecal bacterial flora in patients with liver cirrhosis and hepatic encephalopathy]
- PMID: 7643458
[Effects of lactitol on fecal bacterial flora in patients with liver cirrhosis and hepatic encephalopathy]
Abstract
Lactitol, a non-absorbable synthetic disaccharide, was administered at a dose of 36g/day for 3-4 weeks to 8 patients with liver cirrhosis and hepatic encephalopathy in order to investigate its effects on fecal bacterial flora and clinical symptoms of hepatic encephalopathy. Lactitol significantly increased occupation ratio (ratio to total bacterial number) of anaerobic Bifidobacterium (before administration 7.1% --> after 4 weeks 46.0% (p < 0.05) as well as bacterial count of Lactobacillus. On the other hand, bacterial counts of Bacteroides and Clostridium, which are considered to be NH3-producing bacteria, and that of total aerobic bacteria were not markedly changed, but their occupation ratio were decreased after the administration. Further, tendencies toward decreased fecal pH, increased frequency of defecation and soft stools were observed. As for clinical efficacy, a decrease in blood ammonia concentration, improvement in mental state and flapping tremor were also observed.
Similar articles
-
Effect of lactitol and lactulose administration on the fecal flora in cirrhotic patients.J Clin Gastroenterol. 1990 Aug;12(4):433-6. doi: 10.1097/00004836-199008000-00016. J Clin Gastroenterol. 1990. PMID: 2398251 Clinical Trial.
-
[Lactitol and neomycin: monotherapy or combined therapy in the prevention and treatment of hepatic encephalopathy?].Clin Ter. 1989 Apr 30;129(2):105-11. Clin Ter. 1989. PMID: 2525995 Italian.
-
The effect of lactulose and lactitol administration on fecal fat excretion in patients with liver cirrhosis.J Clin Gastroenterol. 1992 Sep;15(2):125-7. doi: 10.1097/00004836-199209000-00009. J Clin Gastroenterol. 1992. PMID: 1401823 Clinical Trial.
-
Review article: bacterial flora and pathogenesis in hepatic encephalopathy.Aliment Pharmacol Ther. 2007 Feb;25 Suppl 1:17-22. doi: 10.1111/j.1746-6342.2006.03217.x. Aliment Pharmacol Ther. 2007. PMID: 17295848 Review.
-
Current state of knowledge of hepatic encephalopathy (part III): non-absorbable disaccharides.Metab Brain Dis. 2016 Dec;31(6):1361-1364. doi: 10.1007/s11011-016-9910-2. Epub 2016 Sep 16. Metab Brain Dis. 2016. PMID: 27638474 Free PMC article. Review.
Cited by
-
Effects of low doses of lactitol on faecal microflora, pH, short chain fatty acids and gastrointestinal symptomology.Eur J Nutr. 2007 Sep;46(6):307-14. doi: 10.1007/s00394-007-0666-7. Epub 2007 Jul 11. Eur J Nutr. 2007. PMID: 17623227 Clinical Trial.
-
Gut Microbes and Hepatic Encephalopathy: From the Old Concepts to New Perspectives.Front Cell Dev Biol. 2021 Nov 26;9:748253. doi: 10.3389/fcell.2021.748253. eCollection 2021. Front Cell Dev Biol. 2021. PMID: 34900994 Free PMC article. Review.
-
Sarcopenia in cirrhosis: Prospects for therapy targeted to gut microbiota.World J Gastroenterol. 2023 Jul 21;29(27):4236-4251. doi: 10.3748/wjg.v29.i27.4236. World J Gastroenterol. 2023. PMID: 37545638 Free PMC article. Review.
-
The role of microbiota in hepatic encephalopathy.Gut Microbes. 2014 May-Jun;5(3):397-403. doi: 10.4161/gmic.28684. Epub 2014 Apr 1. Gut Microbes. 2014. PMID: 24690956 Free PMC article. Review.
-
Altered Microbiome in Patients With Cirrhosis and Complications.Clin Gastroenterol Hepatol. 2019 Jan;17(2):307-321. doi: 10.1016/j.cgh.2018.08.008. Epub 2018 Aug 9. Clin Gastroenterol Hepatol. 2019. PMID: 30099098 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials